...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Hepatology: Official Journal of the American Association for the Study of Liver Diseases >Health-related quality of life and sorafenib.
【24h】

Health-related quality of life and sorafenib.

机译：与健康有关的生活质量和索拉非尼。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

I read the very interesting article by Finn about sorafenib, the first systemic agent showing a survival advantage when it is used to treat patients with hepatocellular carcinoma. Finn pointed out common and predictable toxicities, including hand-skin reactions, anorexia, and diarrhea, which were experienced by 15% to 40% of the treated patients. However, Finn did not mention the importance of health-related quality of life (HRQOL) with respect to the potential side effects of hepatocellular carcinoma treatment and wrote only a few words about the cost of the drug. The growth of health care costs continues to outpace our ability to pay for health care in the future. We need to know not only the clinical efficacy of the drug but also its cost-effectiveness and the HRQOL of patients randomized between a placebo and sorafenib.
机译：我读了Finn关于sorafenib的一篇非常有趣的文章，索拉非尼是第一种在治疗肝细胞癌患者时显示出生存优势的全身性药物。 Finn指出常见和可预测的毒性反应，包括手皮反应，食欲不振和腹泻，这在接受治疗的患者中占15％至40％。但是，Finn并未提及与健康相关的生活质量（HRQOL）在肝细胞癌治疗的潜在副作用方面的重要性，并且只写了几句有关该药的价格。医疗保健费用的增长继续超过我​​们将来支付医疗保健费用的能力。我们不仅需要了解该药物的临床疗效，还需要了解其成本效益以及在安慰剂和索拉非尼之间随机分组的患者的HRQOL。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号